Zydus receives final approval from the USFDA for Ketorolac Tromethamine Tablets

Zydus receives final approval from the USFDA for Ketorolac Tromethamine Tablets Ahmedabad, India, 22 October, 2022 Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) has received final approval from the United States Food and Drug Administration (USFDA) to market Ketorolac Tromethamine Tablets USP, 10 mg (USRLD: Toradol®). Ketorolac Tromethamine Tablets are indicated to relieve moderately severe pain, usually after surgery. The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India. Ketorolac Tromethamine Tablets had annual sales of USD 17mn in the United States according to IQVIA data (IQVIA MAT Aug 2022). The group now has 328 approvals and has so far filed over 428 * ANDAs since the commencement of the filing process in FY 2003-04. (*as of 30th June 2022) ****

The release as fetched from its publisher. zyduslife.com ↗